Yan Xu
Research Subjects
Yan Xu has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Guiying Hong
4 shared publicationsLinnea M. Baudhuin
Department of Cancer Biology, The Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
4 shared publicationsYi-Jin Xiao
Department of Cancer Biology The Lerner Research Institute Cleveland Clinic Foundation 9500 Euclid Avenue Cleveland OHIO 44195
4 shared publicationsKui Zhu
3 shared publicationsJerome Belinson
2 shared publicationsYing Jiang
Department of Cancer Biology, The Lerner Research Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
2 shared publications
Latest Publications
- 1 September 2005
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 22 (5) , 369-376
KiSS1 Suppresses Metastasis in Human Ovarian Cancer via Inhibition of Protein Kinase C Alpha
Metastasis is a vital target for cancer treatment, since the majority of cancer patients die from metastatic, rather than the primary disease. KiSS1 has been identified as a metastasis suppressor gene in melanoma and breast carcinomas. We show here that KiSS1 is also a metastasis suppressor in human ovarian cancer. Overexpression of KiSS1 in ovarian cancer cells inhibits cell migration induced by serum or lysophosphatidic acid (LPA), and colonization in soft agar, but not cell proliferation, representing the characteristics of a metastasis suppressor gene. Furthermore, using an experimental metastatic mouse model, we show that expression of KiSS1 in SKOV3 ovarian cancer cells suppresses >50% metastatic colonization in mice (P < 0.0001). We find that activating protein kinase C (PKC) reverses about 80% of the inhibited cell migration induced by KiSS1, while down-regulation of PKCα with shRNA restores KiSS1 effect, providing evidence that inhibiting PKCα may be an important mechanism of the effect of KiSS1. These results suggest that KiSS1 is a metastasis suppressor of ovarian cancer and may be a potential molecular target for the treatment.
- 1 September 2005
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 22 (5) , 369-376
KiSS1 Suppresses Metastasis in Human Ovarian Cancer via Inhibition of Protein Kinase C Alpha
Metastasis is a vital target for cancer treatment, since the majority of cancer patients die from metastatic, rather than the primary disease. KiSS1 has been identified as a metastasis suppressor gene in melanoma and breast carcinomas. We show here that KiSS1 is also a metastasis suppressor in human ovarian cancer. Overexpression of KiSS1 in ovarian cancer cells inhibits cell migration induced by serum or lysophosphatidic acid (LPA), and colonization in soft agar, but not cell proliferation, representing the characteristics of a metastasis suppressor gene. Furthermore, using an experimental metastatic mouse model, we show that expression of KiSS1 in SKOV3 ovarian cancer cells suppresses >50% metastatic colonization in mice (P < 0.0001). We find that activating protein kinase C (PKC) reverses about 80% of the inhibited cell migration induced by KiSS1, while down-regulation of PKCα with shRNA restores KiSS1 effect, providing evidence that inhibiting PKCα may be an important mechanism of the effect of KiSS1. These results suggest that KiSS1 is a metastasis suppressor of ovarian cancer and may be a potential molecular target for the treatment.
- Open Access
- 4 December 2003
- Published by Wiley in The FASEB Journal
- Vol. 18 (2) , 1-17
S1P 3 ‐mediated Akt activation and crosstalk with platelet‐derived growth factor receptor (PDGFR)
Akt plays a pivotal role in cell survival and tumorigenesis. We investigated the potential interaction between sphingosine‐1‐phosphate (S1P) and platelet‐derived growth factor (PDGF) in the Akt signaling pathway. Using mouse embryonic fibroblasts (MEFs) from S1P receptor knockout mice, we show here that S1P 3 was required for S473 phosphorylation of Akt by S1P. In addition, S1P‐stimulated activation of Akt, but not ERK, was blocked by a PDGF receptor (PDGFR)‐specific inhibitor, AG1296, suggesting a S1P 3 ‐mediated specific crosstalk between the Akt signaling pathways of S1P and PDGFR in MEFs. We investigated this crosstalk under different conditions and found that both Akt and ERK activation induced by S1P, but not lysophosphatidic acid (LPA), in HEY ovarian cancer cells required PDGFR but not epidermal growth factor receptor (EGFR) or insulin‐like growth factor‐I receptor (IGFR). Importantly, S1P induced a G i ‐dependent tyrosine phosphorylation of PDGFR in HEY cells. This dependence on PDGFR in S1P‐induced Akt activation was also observed in A2780, T47D, and HMEC‐1 cells (which express S1P 3 ), but not in PC‐3 or GI‐101A cells (which do not express S1P 3 ), further supporting that S1P 3 mediates the crosstalk between S1P and PDGFR. This is the first report demonstrating a unique interaction between S1P 3 and PDGFR, in addition to demonstrating a specific role for S1P 3 in S1P‐induced Akt activation.
- 4 December 2003
- Published by Wiley in The FASEB Journal
- Vol. 18 (2) , 1-17
Open AccessS1P 3 ‐mediated Akt activation and crosstalk with platelet‐derived growth factor receptor (PDGFR)
Akt plays a pivotal role in cell survival and tumorigenesis. We investigated the potential interaction between sphingosine‐1‐phosphate (S1P) and platelet‐derived growth factor (PDGF) in the Akt signaling pathway. Using mouse embryonic fibroblasts (MEFs) from S1P receptor knockout mice, we show here that S1P 3 was required for S473 phosphorylation of Akt by S1P. In addition, S1P‐stimulated activation of Akt, but not ERK, was blocked by a PDGF receptor (PDGFR)‐specific inhibitor, AG1296, suggesting a S1P 3 ‐mediated specific crosstalk between the Akt signaling pathways of S1P and PDGFR in MEFs. We investigated this crosstalk under different conditions and found that both Akt and ERK activation induced by S1P, but not lysophosphatidic acid (LPA), in HEY ovarian cancer cells required PDGFR but not epidermal growth factor receptor (EGFR) or insulin‐like growth factor‐I receptor (IGFR). Importantly, S1P induced a G i ‐dependent tyrosine phosphorylation of PDGFR in HEY cells. This dependence on PDGFR in S1P‐induced Akt activation was also observed in A2780, T47D, and HMEC‐1 cells (which express S1P 3 ), but not in PC‐3 or GI‐101A cells (which do not express S1P 3 ), further supporting that S1P 3 mediates the crosstalk between S1P and PDGFR. This is the first report demonstrating a unique interaction between S1P 3 and PDGFR, in addition to demonstrating a specific role for S1P 3 in S1P‐induced Akt activation.
- Open Access
- 3 June 2003
- Published by Wiley in The FASEB Journal
- Vol. 17 (11) , 1-24
A novel laminin‐induced lysophosphatidic acid autocrine loop in the migration of ovarian cancer cells
We have reported previously that levels of lysophosphatidic acid (LPA) are elevated in the blood and ascites from patients with ovarian cancer. LPA stimulates proliferation of ovarian cancer cells and has been proposed as an autocrine growth factor. Here, we show that a novel autocrine loop of LPA promotes the migration of ovarian cancer cells, which is a critical step of tumor metastasis. We report that laminin, but not other extracellular matrix proteins, induces LPA production in ovarian cancer cells. A neutralizing antibody against β 1 integrin and a calcium‐independent phospholipase A 2 ‐specific inhibitor, HELSS, block both LPA production and the haptotactic activity of laminin. Exogenously added LPA restores the migratory ability of HEY ovarian cancer cells to laminin. These data suggest that laminin‐induced cell migration is mediated by LPA. We further show that a specific receptor for LPA, LPA 3 , is required for mediating the chemotactic activity of LPA. In addition, we show that cytosolic PLA 2 is required for cell migration and its activation is phosphatidylinositol‐3 kinase‐dependent. These findings have revealed a new mechanism of crosstalk between a β 1 integrin receptor and a G protein‐coupled receptor.
- 3 June 2003
- Published by Wiley in The FASEB Journal
- Vol. 17 (11) , 1-24
Open AccessA novel laminin‐induced lysophosphatidic acid autocrine loop in the migration of ovarian cancer cells
We have reported previously that levels of lysophosphatidic acid (LPA) are elevated in the blood and ascites from patients with ovarian cancer. LPA stimulates proliferation of ovarian cancer cells and has been proposed as an autocrine growth factor. Here, we show that a novel autocrine loop of LPA promotes the migration of ovarian cancer cells, which is a critical step of tumor metastasis. We report that laminin, but not other extracellular matrix proteins, induces LPA production in ovarian cancer cells. A neutralizing antibody against β 1 integrin and a calcium‐independent phospholipase A 2 ‐specific inhibitor, HELSS, block both LPA production and the haptotactic activity of laminin. Exogenously added LPA restores the migratory ability of HEY ovarian cancer cells to laminin. These data suggest that laminin‐induced cell migration is mediated by LPA. We further show that a specific receptor for LPA, LPA 3 , is required for mediating the chemotactic activity of LPA. In addition, we show that cytosolic PLA 2 is required for cell migration and its activation is phosphatidylinositol‐3 kinase‐dependent. These findings have revealed a new mechanism of crosstalk between a β 1 integrin receptor and a G protein‐coupled receptor.
- 1 March 2003
- Vol. 3 (1) , 23-32
Unfolding the pathophysiological role of bioactive lysophospholipids.
Lysophospholipids (LPLs), including glycerol- and sphingoid-based lipids, stimulate cell signaling and play important pathophysiological roles in humans and other animals. These LPLs include lysophosphatidic acid (LPA), lysophosphatidylinositol (LPI), lysophosphatidylcholine (LPC), lysophosphatidylserine (LPS), sphingosine-1-phosphate (S1P), and sphingosylphosphorylcholine (SPC). Analyses of LPLs in human body fluids from subjects with different pathophysiological conditions reveal not only the relevance of LPLs in human diseases, but also their potential application as biomarkers and/or therapeutic targets. In recent years, the identification and/or characterization of the plasma membrane receptors for LPLs and enzymes regulating the metabolism of LPLs have greatly facilitated our understanding of their role and signaling properties. In vitro and in vivo functional and signaling studies have revealed the broad and potent biological effects of LPLs and the mechanisms of LPL actions in different cellular systems. Development of specific antagonists for each of the LPL receptors will provide powerful tools for dissecting signaling pathways mediated by receptor subtypes. More importantly, these antagonists may serve as therapeutics for relevant diseases. Genetic depletion of LPL receptors in mice has provided and will continue to provide critical information on the pathophysiological roles of LPL receptors. It is important to further evaluate the significance of targeting these bioactive LPL receptors, their downstream signaling molecules, and/or metabolic enzymes in the treatment of cancers and other diseases.
- 1 March 2003
- Vol. 3 (1) , 23-32
Unfolding the pathophysiological role of bioactive lysophospholipids.
Lysophospholipids (LPLs), including glycerol- and sphingoid-based lipids, stimulate cell signaling and play important pathophysiological roles in humans and other animals. These LPLs include lysophosphatidic acid (LPA), lysophosphatidylinositol (LPI), lysophosphatidylcholine (LPC), lysophosphatidylserine (LPS), sphingosine-1-phosphate (S1P), and sphingosylphosphorylcholine (SPC). Analyses of LPLs in human body fluids from subjects with different pathophysiological conditions reveal not only the relevance of LPLs in human diseases, but also their potential application as biomarkers and/or therapeutic targets. In recent years, the identification and/or characterization of the plasma membrane receptors for LPLs and enzymes regulating the metabolism of LPLs have greatly facilitated our understanding of their role and signaling properties. In vitro and in vivo functional and signaling studies have revealed the broad and potent biological effects of LPLs and the mechanisms of LPL actions in different cellular systems. Development of specific antagonists for each of the LPL receptors will provide powerful tools for dissecting signaling pathways mediated by receptor subtypes. More importantly, these antagonists may serve as therapeutics for relevant diseases. Genetic depletion of LPL receptors in mice has provided and will continue to provide critical information on the pathophysiological roles of LPL receptors. It is important to further evaluate the significance of targeting these bioactive LPL receptors, their downstream signaling molecules, and/or metabolic enzymes in the treatment of cancers and other diseases.
- Open Access
- 1 March 2002
- Published by Elsevier in Journal of Lipid Research
- Vol. 43 (3) , 463-476
Role of ether-linked lysophosphatidic acids in ovarian cancer cells
- 1 March 2002
- Published by Elsevier in Journal of Lipid Research
- Vol. 43 (3) , 463-476
Open AccessRole of ether-linked lysophosphatidic acids in ovarian cancer cells
- RetractedOpen Access
- 1 November 2001
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 276 (44) , 41325-41335
Sphingosylphosphorylcholine and Lysophosphatidylcholine Are Ligands for the G Protein-coupled Receptor GPR4
- 1 November 2001
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 276 (44) , 41325-41335
RetractedOpen AccessSphingosylphosphorylcholine and Lysophosphatidylcholine Are Ligands for the G Protein-coupled Receptor GPR4
- Retracted
- 4 April 2000
- Published by Springer Nature in Nature Cell Biology
- Vol. 2 (5) , 261-267
Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1
Sphingosylphosphorylcholine (SPC) is a bioactive lipid that acts as an intracellular and extracellular signalling molecule in numerous biological processes. Many of the cellular actions of SPC are believed to be mediated by the activation of unidentified G-protein-coupled receptors. Here we show that SPC is a high-affinity ligand for an orphan receptor, ovarian cancer G-protein-coupled receptor 1 (OGR1). In OGR1-transfected cells, SPC binds to OGR1 with high affinity (Kd = 33.3 nM) and high specificity and transiently increases intracellular calcium. The specific binding of SPC to OGR1 also activates p42/44 mitogen-activated protein kinases (MAP kinases) and inhibits cell proliferation. In addition, SPC causes internalization of OGR1 in a structurally specific manner.
- 4 April 2000
- Published by Springer Nature in Nature Cell Biology
- Vol. 2 (5) , 261-267
RetractedSphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1
Sphingosylphosphorylcholine (SPC) is a bioactive lipid that acts as an intracellular and extracellular signalling molecule in numerous biological processes. Many of the cellular actions of SPC are believed to be mediated by the activation of unidentified G-protein-coupled receptors. Here we show that SPC is a high-affinity ligand for an orphan receptor, ovarian cancer G-protein-coupled receptor 1 (OGR1). In OGR1-transfected cells, SPC binds to OGR1 with high affinity (Kd = 33.3 nM) and high specificity and transiently increases intracellular calcium. The specific binding of SPC to OGR1 also activates p42/44 mitogen-activated protein kinases (MAP kinases) and inhibits cell proliferation. In addition, SPC causes internalization of OGR1 in a structurally specific manner.
- 1 April 2000
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 905 (1) , 242-259
Evaluation of Plasma Lysophospholipids for Diagnostic Significance Using Electrospray Ionization Mass Spectrometry (ESI‐MS) Analyses
Abstract: We previously reported that lysophosphatidic acid (LPA) represents a potential biomarker for ovarian and other gynecologic cancers. To further improve the accuracy and potentially increase the sensitivity and specificity of the assay, we developed an electrospray ionization mass spectrometry (ESI‐MS)‐based method to analyze LPA and related lysophospholipids. LPA, lysophosphatidylinositol (LPI), lysophosphatidylserine (LPS), and lysophosphatidylcholine (LPC) could be detected with high sensitivity (in low pmol range) using this method. Standard curves were established for quantitative analysis. LPA and closely related lysophospholipids isolated from thin‐layer chromatography (TLC) plates were analyzed directly by ESI‐MS. This ESI‐MS‐based assay allows simultaneous detection and quantitation of all different species of LPAs and LPIs in a sample over a range of at least 5–300 pmol. Moreover, this test was at least 50 times more sensitive when a multiple reaction monitoring (MRM) mode was used. Using these protocols in a limited set of analyses, we found that both LPA and LPI were elevated in patients with ovarian cancer.
- 1 April 2000
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 905 (1) , 242-259
Evaluation of Plasma Lysophospholipids for Diagnostic Significance Using Electrospray Ionization Mass Spectrometry (ESI‐MS) Analyses
Abstract: We previously reported that lysophosphatidic acid (LPA) represents a potential biomarker for ovarian and other gynecologic cancers. To further improve the accuracy and potentially increase the sensitivity and specificity of the assay, we developed an electrospray ionization mass spectrometry (ESI‐MS)‐based method to analyze LPA and related lysophospholipids. LPA, lysophosphatidylinositol (LPI), lysophosphatidylserine (LPS), and lysophosphatidylcholine (LPC) could be detected with high sensitivity (in low pmol range) using this method. Standard curves were established for quantitative analysis. LPA and closely related lysophospholipids isolated from thin‐layer chromatography (TLC) plates were analyzed directly by ESI‐MS. This ESI‐MS‐based assay allows simultaneous detection and quantitation of all different species of LPAs and LPIs in a sample over a range of at least 5–300 pmol. Moreover, this test was at least 50 times more sensitive when a multiple reaction monitoring (MRM) mode was used. Using these protocols in a limited set of analyses, we found that both LPA and LPI were elevated in patients with ovarian cancer.